Predictors of remission and survival: multivariate analysis
| Baseline variable . | PR . | CR . | OS . |
|---|---|---|---|
| FVIII activity <1 IU/dL | 0.52 (0.33-0.81)** | 0.49 (0.29-0.85)* | 2.40 (1.10-5.22)* |
| Inhibitor concentration >20 BU/mL | 0.77 (0.49-1.21) | 0.75 (0.43-1.29) | 1.20 (0.54-2.67) |
| Female gender | 1.22 (0.77-1.91) | 1.30 (0.76-2.24) | 0.58 (0.26-1.31) |
| Age >74 y | 0.94 (0.58-1.50) | 0.76 (0.43-1.32) | 1.76 (0.82-3.78) |
| Underlying disorder | |||
| Autoimmunity | 1.32 (0.77-2.28) | 0.88 (0.45-1.72) | 1.02 (0.36-2.84) |
| Malignancy | 0.58 (0.28-1.21) | 0.62 (0.27-1.44) | 2.91 (1.12-7.52)* |
| Pregnancy | 0.61 (0.23-1.65) | 0.74 (0.27-2.04) | — |
| WHO-PS >2 | 0.76 (0.48-1.21) | 0.39 (0.21-0.72)** | 3.38 (1.55-7.37)** |
| Baseline variable . | PR . | CR . | OS . |
|---|---|---|---|
| FVIII activity <1 IU/dL | 0.52 (0.33-0.81)** | 0.49 (0.29-0.85)* | 2.40 (1.10-5.22)* |
| Inhibitor concentration >20 BU/mL | 0.77 (0.49-1.21) | 0.75 (0.43-1.29) | 1.20 (0.54-2.67) |
| Female gender | 1.22 (0.77-1.91) | 1.30 (0.76-2.24) | 0.58 (0.26-1.31) |
| Age >74 y | 0.94 (0.58-1.50) | 0.76 (0.43-1.32) | 1.76 (0.82-3.78) |
| Underlying disorder | |||
| Autoimmunity | 1.32 (0.77-2.28) | 0.88 (0.45-1.72) | 1.02 (0.36-2.84) |
| Malignancy | 0.58 (0.28-1.21) | 0.62 (0.27-1.44) | 2.91 (1.12-7.52)* |
| Pregnancy | 0.61 (0.23-1.65) | 0.74 (0.27-2.04) | — |
| WHO-PS >2 | 0.76 (0.48-1.21) | 0.39 (0.21-0.72)** | 3.38 (1.55-7.37)** |